Research programme: biodefence therapeutics - Callisto

Drug Profile

Research programme: biodefence therapeutics - Callisto

Alternative Names: 6343 peptide; Anti Toxic Shock antibody - Callisto; ATS antibody - Callisto; Biodefense therapeutics - Callisto; TSS Mab

Latest Information Update: 21 Jan 2013

Price : $50

At a glance

  • Originator Callisto Pharmaceuticals
  • Developer Synergy Pharmaceuticals Inc
  • Class Monoclonal antibodies; Peptides; Vaccines
  • Mechanism of Action T cell activation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Staphylococcal infections; Streptococcal infections

Most Recent Events

  • 17 Jan 2013 Callisto Pharmaceuticals has been merged into Synergy Pharmaceuticals Inc
  • 31 Jan 2006 Data presented at the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2005) have been added to the Bacterial Infections pharmacodynamics section
  • 01 Apr 2005 Preclinical trials in Staphylococcal infections in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top